Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2.5 million on the bid @ .27
Etrade. Is this correct?
I get it, you don't know. Thanks.
And you know this how? Do you work for the Baker Brothers?
Hands down post of the day. congrats
Shorty has been triggered.
Absolutely!
I don't have much hope for the Pfizer pill being effective. We need Brilacidin.
ipix will probably close green again today.Go ipix!
You just knocked it out of the park. Great work
"For me it's still about 50%"
Did you just pull that number out of your arse? Please tell me how many trials Brilacidin has failed. With all the positive information coming from George Mason University studying Brilacidin as an antiviral, you decide 50% is a fair number for success. Laughable.
"underestimating the real significant chance of failure in this trial"
For someone who claims to be an investor in ipix, this is very strange wording. Can you explain the "Real Significant" part of that sentence.
I agree. Green close. Go ipix. Time is running out for the shorts.
#93, you must be missing someone.
If I was short I'd be very nervous.
2021 American Society of Virology Annual Meeting
July 21, 2021
Antiviral data data related to Brilacidin, the Company’s defensin-mimetic drug candidate, has been accepted for an Oral Presentation at the American Society of Virology’s 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.
The presentation—“Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as Broad Spectrum Inhibitor of Acutely Infectious Viruses”—is based on ongoing independent laboratory research being conducted by scientists at George Mason University (GMU)/National Center for Biodefense and Infectious Diseases (NCBID).
Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.
Further details on the Brilacidin ASV 2021 presentation will be forthcoming.
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and has fully enrolled 120 patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.
I know it's crazy and yet there are some who will tell you there's nothing going on behind the curtain.
WAKEFIELD, MA – June 3, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Looks like .40's next week.
Looking forward to a Boba Ride to $4.
I get a tingle from Brilacidin every time I think about how good the trial results could be. Go ipix
Next stop 100%. I'd be nervous if I was short ipix. Fact!
WAKEFIELD, MA – May 27, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.
I agree, I can easily see full enrollment achieved next week.
Gonna be a fun June.
Hugh bid at .21 million plus.
Seems like this is not a scam company.
WAKEFIELD, MA – March 10, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learning (Artificial Intelligence) model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2, the virus responsible for COVID-19. Published in Bioinformatics, by Oxford University Press, the Machine Learning ranking is based on a compound’s predicted ability, due to its physicochemical properties, to bind to coronavirus proteins and thus inhibit viral replication. The predictive framework used in this research was built by assessing the structure of the main proteins of almost 100 different viral organisms, making the model generalizable to multiple viruses, according to the study’s authors.
Does it sound like Brilacidin has safety issues?
WAKEFIELD, MA – April 5, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitoring Committee (DMC) completed its scheduled review of interim safety data in the Company’s randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.
Does this sound like ipix is a scam company?
WAKEFIELD, MA – April 14, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University.
This works for me:
“It was a busy and productive quarter for us,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Patient enrollment in the Phase 2 study of Brilacidin for COVID-19 is moving along quickly, far faster in recruitment than other COVID-19 studies we’ve seen in industry reports. We are optimistic about Brilacidin’s COVID-19 treatment prospects, and are further encouraged by the broad spectrum antiviral properties Brilacidin is exhibiting based on ongoing lab research in multiple viruses.”
Locked and loaded, ready for the hyperbolic rise in the coming weeks. Looking for enrollment news soon.
The clock is ticking, full enrollment will be here shortly. I've got my ticket for the ride. I wouldn't want to be shorting ipix.
They're not going to be able to keep the lid on ipix for very much longer. The next several weeks could get very interesting. Going green
Best cover your short positions, ipix is going much higher.
Dr. DeGrado Lab
https://pharm.ucsf.edu/degrado
Added 50K today, thanks for all the info you provide. Go ipix.
What the heck is going on? love it.
Board spectrum antiviral. Not just covid19.
Sorry, but this is a very uneducated opinion.
I think your list is outdated, I have it as #87...
Could Brilacidin be a possible treatment for covid19 long hauler patients?
Easy to say, how about you prove it.